CureVac (NSDQ:CVAC) and GSK (NYSE:GSK) have announced the dosing of the first participant in a Phase 1 study of a multivalent influenza vaccine built on a second-generation mRNA backbone. The study is based in Panama and will enroll approximately 240 subjects. CVAC shares increased 2.27% to $19.34 in mid-day trading. At various points last year,…
Moderna doses the first patient with its mRNA Epstein-Barr virus vaccine candidate
Moderna (NSDQ:MRNA) has dosed the first volunteer in the Phase 1 Eclipse study of mRNA-1189, an Epstein-Barr virus vaccine candidate. The study will take place at roughly 15 sites in the U.S. and involve approximately 272 healthy adults between the ages of 18 and 30. The study will be randomized, observer-blind, placebo-controlled and involve a range of doses.…
Pfizer and BioNTech set their sights on developing mRNA-based shingles vaccine
Pfizer Inc. (NYSE:PFE) and mRNA vaccine specialist BioNTech SE (NSDQ:BNTX) will collaborate to develop an mRNA-based vaccine to prevent the herpes zoster virus (shingles). Roughly one million people in the U.S. get shingles each year, according to the CDC. Currently, the two-dose Shingrix shingles vaccine from GSK (NYSE:GSK) is the only such product available in the U.S. market.…
Moderna debuts fellowship program for young researchers focusing on mRNA therapies
Messenger RNA (mRNA) therapeutics and vaccines may offer significant promise, but few scientists specialize in the technology. Moderna (NSDQ: MRNA) aims to inspire a new generation of scientists and clinicians to focus on mRNA research with a new fellowship program. The program will support a range of applications within medicine, basic research, epidemiology, pharmacology, nursing…
Sanofi completes Translate Bio acquisition
Sanofi (NSDQ:SNY) announced today that it has completed the purchase of its mRNA partner Translate Bio. The previously announced deal, according to Sanofi, accelerates the French pharma giant’s efforts to develop transformative vaccines and therapies using mRNA technology. The deal comes during a year in which mRNA-based Moderna (NSDQ:MRNA) and Pfizer-BioNTech (NYSE:PFE/NSDQ:BNTX) COVID-19 vaccines are…
CureVac’s interim vaccine efficacy is 47% in Phase 2b/3 study
Germany-based CureVac (NSDQ:CVAC) announced that its mRNA vaccine was 47% effective against COVID-19 in a second interim analysis of a pivotal study involving approximately 40,000 participants in 10 countries. The rise of COVID-19 variants played a role in the disappointing results. At least 13 COVID-19 variants were present in the study population who contracted the…